Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $139.00

Kymera Therapeutics (NASDAQ:KYMR) had its price objective upped by BTIG Research from $134.00 to $139.00 in a research report released on Thursday morning,Benzinga reports. BTIG Research currently has a buy rating on the stock.

A number of other equities research analysts have also issued reports on the company. Royal Bank Of Canada lowered Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and increased their price target for the company from $106.00 to $115.00 in a research report on Monday, July 13th. Mizuho boosted their target price on shares of Kymera Therapeutics from $120.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. Guggenheim increased their target price on Kymera Therapeutics from $135.00 to $170.00 and gave the company a “buy” rating in a report on Monday, August 31st. Raymond James Financial restated an “outperform” rating on shares of Kymera Therapeutics in a research note on Thursday. Finally, Loop Capital set a $132.00 price target on Kymera Therapeutics in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $137.92.

Kymera Therapeutics Stock Up 3.3%

Shares of KYMR opened at $126.63 on Thursday. Kymera Therapeutics has a fifty-two week low of $55.66 and a fifty-two week high of $130.05. The firm’s 50 day moving average price is $114.93 and its 200 day moving average price is $96.35. The company has a market cap of $10.53 billion, a P/E ratio of -34.98 and a beta of 1.98.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 22.65% and a negative net margin of 285.33%. The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. During the same quarter last year, the company earned ($0.94) earnings per share. Kymera Therapeutics’s quarterly revenue was up .0% compared to the same quarter last year. Research analysts forecast that Kymera Therapeutics will post -3.90 earnings per share for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares in the company, valued at $75,855,438.40. This represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Brian Adams sold 6,371 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total value of $744,323.93. Following the transaction, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 15.98% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

A number of large investors have recently made changes to their positions in the company. Merck & Co. Inc. purchased a new stake in shares of Kymera Therapeutics in the second quarter valued at about $88,544,161. Legal & General Group Plc purchased a new position in Kymera Therapeutics during the second quarter worth about $4,155,000. Deutsche Bank AG purchased a new position in shares of Kymera Therapeutics during the 2nd quarter worth about $12,161,000. Eagle Health Investments LP acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at $19,052,000. Finally, Bank of America Corp DE acquired a new stake in Kymera Therapeutics during the second quarter worth about $43,378,000.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported positive Phase 1 results for KT-579, showing deep and sustained IRF5 degradation, strong modulation of disease-relevant biomarkers, and a favorable safety profile. The data support continued development of the company’s immunology pipeline. Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: Truist Financial reaffirmed its “buy” rating and raised its price target from $136 to $150, implying further upside based on the current trading level. Truist Securities Adjusts Price Target on Kymera Therapeutics
• Positive Sentiment: BTIG Research raised its target from $134 to $139 and maintained a “buy” rating, adding to the favorable analyst sentiment.
• Neutral Sentiment: Kymera provided a Phase 1 update on the formulation study for KT-621, offering investors additional information on the program’s ongoing clinical development. KT-621 Formulation Study Update
• Neutral Sentiment: RBC increased its price target from $112 to $116 but retained a “sector perform” rating, signaling limited conviction at the current valuation.
• Negative Sentiment: Third-quarter results missed expectations: adjusted loss was $1.32 per share versus a $1.26 consensus loss, while revenue of $1.35 million was below the $3.28 million estimate. The net loss also widened year over year, highlighting ongoing cash-burn and execution risks. Kymera Therapeutics Q3 Net Loss Widens

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.